An interventional study of blood sample and cerebro-spinal fluid in Multiple Sclerosis and Clinically Isolated Syndrome, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Multiple Sclerosis by University Hospital, Bordeaux — 3 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · University Hospital, Bordeaux.
Among the 17 studies in Multiple Sclerosis by University Hospital, Bordeaux, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2021, is one of 11 with no phase, and was the 11th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 17 studies in Multiple Sclerosis by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Bordeaux · Sites in France
Ages 25–35 · Women only · Healthy volunteers
University Hospital, Bordeaux · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2021.
This study's planned enrollment of 150 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 65 across the 13 interventional studies, 176 across the 4 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
1 of the studies in Multiple Sclerosis by University Hospital, Bordeaux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04798651University Hospital, BordeauxPathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Multiple Sclerosis by University Hospital, Bordeaux, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.
Multiple sclerosis (MS) is a chronic autoimmune disease damaging the central nervous system (CNS). MS is categorized into several distinct forms according to clinical symptoms and medical examinations. Relapsing-remitting multiple sclerosis (RRMS) is characterized by attacks of worsening neurologic function, followed by partial or complete recovery periods. Patients can also present a gradual but steady progression of the disease (progressive forms). While several treatment options are currently available, no treatment completely stops the disease progression. Therefore, a deeper understanding regarding the mechanism of the disease development is essential to generate more efficient treatment strategies. CD4 T cells are known to be significantly involved in the formation of the CNS lesions characteristic of MS.The investigators hypothesize that different types of B and CD4 T cells play major roles in different forms of the disease. They will determine the phenotype and functions of the cells from the immune system particularly B and CD4 T cells present in the blood and cerebro-spinal fluid (CSF) of patients diagnosed with multiple sclerosis or presenting a clinically isolated syndrome.
The study will recruit 150 patients followed in Bordeaux University Hospital and diagnosed for clinically isolated syndrome (CIS) or multiple sclerosis (MS). Blood and CSF will be collected during a scheduled visit to study the properties of cells from the immune system in particular CD4 T cells in multiple sclerosis. Clinical and biological disease activity, treatment and outcomes will be studied in correlation with the properties of blood and CSF lymphocytes. No extra visit will be needed and the blood and CSF samples will be collected at the same times as those collected for clinical purposes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome
Biological: blood sample · Biological: cerebro-spinal fluid
28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
1 ml of cerebro-spinal fluid
Functional and phenotypical characterization of the blood and CSF lymphocytes in MS and CIS patients.
Time frame: At inclusion (day 0)
Quantification of disease activity scores
Expanded Disability Status Scale (EDSS)
Time frame: At inclusion (day 0)
Quantification of disease activity scores
ambulation test
Time frame: At inclusion (day 0)
Number of lesions
evaluated by MRI
Time frame: At inclusion (day 0)
Size of lesions
evaluated by MRI
Time frame: At inclusion (day 0)
Localisation of lesions
evaluated by MRI
Time frame: At inclusion (day 0)
Types of lesions
evaluated by MRI
Time frame: At inclusion (day 0)
duration of the disease
Time frame: At inclusion (day 0)
age at onset and progression
Time frame: At inclusion (day 0)
number of relapses
Time frame: At inclusion (day 0)
date of relapses
Time frame: At inclusion (day 0)
Treatment
Time frame: At inclusion (day 0)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Sep 2027, 72 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 72 months is above that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →